Psoriatic Arthritis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Psoriatic Arthritis Therapeutics Market is Segmented by Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), Immunosuppressants, Biologic Agents, and Other Drug Classes), Route of Administration (Oral, Parenteral, and Other Routes of Administration) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Psoriatic Arthritis Therapeutics Market Size

Single User License
Team License
Corporate License
Book before:
Psoriatic Arthritis Therapeutics Market Summary
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 6.65 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Psoriatic Arthritis Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License


Team License


Corporate License

Book before:

Psoriatic Arthritis Therapeutics Market Analysis

The psoriatic arthritis therapeutic market is expected to register a CAGR of 6.65% over the forecast period.

  • The psoriatic arthritis therapeutic market was significantly impacted by the COVID-19 pandemic, with regulatory bodies suggesting that patients receiving psoriasis treatment are at higher risk of infection. In March 2020, the International Psoriasis Council recommended that physicians discontinue or postpone the prescription of immunosuppressive medications.
  • However, in early 2021, researchers from the Perelman School of Medicine at the University of Pennsylvania, in collaboration with the National Psoriasis Foundation, created guidelines to care for psoriasis patients during the pandemic, finding no evidence that medical interventions to treat psoriasis and psoriatic arthritis should be interrupted or altered to minimize COVID-19 risks. The market has returned to pre-pandemic levels in terms of demand for therapeutics and is expected to experience strong growth in the coming years.
  • Obesity is a major factor that can exacerbate the development of psoriatic arthritis. According to the World Health Organization, 39 million children under the age of 5 were overweight or obese in 2021, with one in five children and adolescents globally being overweight. Lifestyle-related disorders such as anxiety, stress, smoking, and drinking, prevalent in developed countries, have contributed to the increasing incidence of obesity. Other factors, such as an unhealthy lifestyle with alcohol and smoking, may also increase the risk of developing psoriatic arthritis.
  • The development of new therapeutic methods, such as novel drugs with oral administration, is expected to drive market growth. For example, Janssen Pharmaceutical Companies of Johnson & Johnson announced a new posthoc analysis of the Phase 3 DISCOVER program evaluating TREMFYA (guselkumab) in adult patients with active psoriatic arthritis. The results showed that early skin and enthesitis responses predicted longer-term clinical responses, including disease remission, at week 52. Additionally, regulatory authorities approving new drugs, such as AbbVie's SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor for treating adults with active psoriatic arthritis, are also contributing to market growth.
  • Despite the abovementioned factors, the high cost of treatment is expected to hamper market growth.

Psoriatic Arthritis Therapeutics Market Trends

Immunosuppressants Segment is Expected to Hold a Large Share in the Market

  • Immunosuppressants are expected to experience the fastest growth in the psoriasis drugs market during the forecast period. This is due to several factors, including their improved safety and efficacy compared to other drug classes, which has consistently led to increased patient adoption. Major approved antibodies targeting interleukins, such as Taltz (ixekizumab), Cosentyx (secukinumab), Siliq (brodalumab), Tremfya (guselkumab), Ilumya (tildrakizumab), SKYRIZI (risankizumab), and others, are aiding in the adoption of immunosuppressants among the patient population.
  • In addition, the approvals of drugs by regulatory authorities, such as the recent approval of Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, by the United States Food and Drug Administration (USFDA) in September 2022 for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and the approval of the first and only biologic medication, ustekinumab (STELARA), for the treatment of pediatric patients aged 6 years or older with active psoriatic arthritis (PsA) in August 2022, are also contributing to the growth of the segment.
  • Moreover, according to data from PubMed published in December 2022, immunosuppressants used for the treatment of psoriatic arthritis are tolerable and safe, further increasing the demand for these drugs in the market.
  • Therefore, with the significance of immunosuppressants and new launches contributing to the market segment's growth, it is expected to show significant growth over the forecast period.
Psoriatic Arthritis Therapeutics Market: Number of Clinical Studies For Psoriatic Arthritis, By Phase, Global, 2022

North America is Expected to Dominate the Market During the Forecast Period

  • North America is projected to be the dominant player in the psoriatic arthritis therapeutics market due to several factors. One of the primary reasons for this is the region's growing prevalence of psoriatic arthritis and obesity, which has increased awareness of the condition. The Centers for Disease Control and Prevention (CDC) reported in September 2021 that adult obesity rates in the United States are increasing, with twelve states reporting a prevalence of 35% or higher.
  • Developed countries such as the United States and Canada have established healthcare systems that have a rapid adoption rate for new drugs, therapies, and technologies. As a result, expenditures on psoriatic arthritis therapeutics are expected to rise as the disease becomes more prevalent in the future. Furthermore, a study published in April 2022 by the National Library of Medicine indicated that individuals with severe psoriasis are more likely to develop psoriatic arthritis, which increases the severity of the disease.
  • Given these factors, the North American market's growth in psoriatic arthritis therapeutics is expected to accelerate over the forecast period.

Psoriatic Arthritis Therapeutics Market - Growth Rate by Region

Psoriatic Arthritis Therapeutics Industry Overview

The psoriatic arthritis therapeutics market is characterized by moderate fragmentation, with only a few key players dominating the industry. The majority of these key players involved in the research and development of psoriatic arthritis therapy drugs are located in developed countries. Established market leaders with greater funds for research and development and better distribution systems have already established a strong foothold in the market. The presence of major players such as AbbVie Inc., Johnson & Johnson, Pfizer Inc., Sanofi S.A., and Celgene Corporation (Bristol-Myers Squibb) is further intensifying the overall competitive rivalry in the market.

Psoriatic Arthritis Therapeutics Market Leaders

  1. AbbVie Inc

  2. Johnson & Johnson

  3. Pfizer Inc.

  4. Sanofi S.A.

  5. Celgene Corporation (Bristol-Myers Squibb)

*Disclaimer: Major Players sorted in no particular order

Psoriatic Arthritis Therapeutics Market Concentration
bookmark Need More Details on Market Players and Competitors?
Download PDF

Psoriatic Arthritis Therapeutics Market News

  • September 2022: Significant long-term data from the KEEPsAKE trials demonstrated that over 50% of adult psoriatic arthritis patients treated with Skyrizi (risankizumab, 150mg) achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and an American College of Rheumatology 20 (ACR20) response at 100 weeks. These results indicate the effectiveness of Skyrizi in treating psoriatic arthritis.
  • September 2022: The United States Food and Drug Administration (USFDA) granted approval to Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This approval represents a significant milestone for the psoriatic arthritis therapeutics market, as Deucravacitinib has the potential to become a new option for patients suffering from this condition.

Psoriatic Arthritis Therapeutics Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Psoriatic Arthritis Associated with Increasing Obesity

      2. 4.2.2 Strong Product Pipeline

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Drug Class

      1. 5.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

      2. 5.1.2 Disease-Modifying Antirheumatic Drugs (DMARDs)

      3. 5.1.3 Immunosuppressants

      4. 5.1.4 Biologic Agents

      5. 5.1.5 Other Drug Classes

    2. 5.2 By Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Parenteral

      3. 5.2.3 Other Routes of Administration

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer Inc.

      2. 6.1.2 Eisai Inc

      3. 6.1.3 UCB Biosciences Inc

      4. 6.1.4 Sanofi S.A.

      5. 6.1.5 Otsuka Pharmaceutical

      6. 6.1.6 Sumitomo Dainippon Pharma Co

      7. 6.1.7 Johnson & Johnson

      8. 6.1.8 Celgene Corporation (Bristol-Myers Squibb)

      9. 6.1.9 AbbVie Inc.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Psoriatic Arthritis Therapeutics Industry Segmentation

As per the scope of the report, psoriatic arthritis is a form of arthritis that affects some people with psoriasis, a condition that develops red patches on the skin with silvery scales. Psoriatic arthritis therapeutics include drugs that help relieve pain, reduce inflammation, slow the progression of psoriatic arthritis, or directly target parts of the immune system that trigger inflammation. 

The Psoriatic arthritis therapeutics market is segmented by drug class (nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), immunosuppressants, biologic agents, and others), route of administration (oral, parenteral, and others) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. 

The report offers the value (in USD million) for the above segments.

By Drug Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Disease-Modifying Antirheumatic Drugs (DMARDs)
Biologic Agents
Other Drug Classes
By Route of Administration
Other Routes of Administration
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Psoriatic Arthritis Therapeutics Market Research FAQs

The Psoriatic Arthritis Therapeutics Market is projected to register a CAGR of 6.65% during the forecast period (2024-2029)

AbbVie Inc, Johnson & Johnson, Pfizer Inc., Sanofi S.A. and Celgene Corporation (Bristol-Myers Squibb) are the major companies operating in the Psoriatic Arthritis Therapeutics Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Psoriatic Arthritis Therapeutics Market.

The report covers the Psoriatic Arthritis Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Psoriatic Arthritis Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Psoriatic Arthritis Therapeutics Industry Report

Statistics for the 2024 Psoriatic Arthritis Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Psoriatic Arthritis Therapeutics analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Psoriatic Arthritis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)